Scott Campbell

Scott Campbell

Auto-generated profile, based on publicly available information

Scott Campbell

Princess Alexandra Hospital, Queensland Kidney Transplant Service Brisbane Queensland Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2020 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
KMKyoko Miura
Kyoko Miura
MWMandy Way
Mandy Way
ZJZainab Jiyad
Zainab Jiyad
LMLouise Marquart
Louise Marquart
EPElsemieke I. Plasmeijer
Elsemieke I. Plasmeijer
AGAdèle C. Green
Adèle C. Green

3 March 2022 in Journal of Renal Nutrition
Verified
Journal Article
Open access
PDF file
SCSamuel Chan
Samuel Chan
CHCarmel M. Hawley
Carmel M. Hawley
EPElaine M. Pascoe
Elaine M. Pascoe
CCChristopher Cao
Christopher Cao
SCScott B. Campbell
Scott B. Campbell
DJDavid W. Johnson
David W. Johnson
Background Modulating the large intestinal microbiome of kidney transplant recipients (KTR) may reduce infectious complications. The aim of this study was to assess the feasibility of a randomized controlled trial of prebiotics in reducing infections and gastrointestinal symptoms in KTR. Methods Acute KTR were recruited to a double-blind, placebo-controlled, randomized trial at a single kidney transplant center. Patients were provided with prebiotics or placebo for 7 weeks. The primary outcome was feasibility, defined as recruitment of ≥80% of eligible people within 6 months. Secondary outcomes included adherence and tolerability, participant retention in trial, proportions of participants providing serum and stool specimens, self-reported quality of life (QOL), gastrointestinal symptoms and infection events. Results During the 7-week period, 72 patients met eligibility criteria, of whom 60 (83%) consented to participate (mean±SD age 53±12 years; 62% males). Fifty six (78%) participants were randomized (27 intervention and 29 control). While participants receiving intervention experienced reduced gastrointestinal symptoms (-0.28 [IQR -0.67 to 0.08] vs -0.07 [IQR -0.27 to 0], p=0.03), both control and intervention groups were similar in adherence (67% vs. 72%, p=0.36), tolerability (56% vs. 62%, p=0.64), QOL (-0.2 [IQR -0.6 to 0] vs. –0.2 [IQR -0.8 to 0], p=0.82) and infection events (33% vs. 34%, p=0.83). Blood and stool samples were collected from ≥90% of participants in both groups. Conclusions It is feasible to recruit and retain acute KTR in a randomized placebo-controlled trial examining the effect of prebiotics on infections and gastrointestinal symptoms. This study also showed that prebiotics significantly reduced gastrointestinal symptoms.

1 January 2016 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
VDVijayendra Dasari
Vijayendra Dasari
ASAndrea Schuessler
Andrea Schuessler
CSCorey Smith
Corey Smith
YWYide Wong
Yide Wong
JMJohn Miles
John Miles
RKRajiv Khanna
Rajiv Khanna
An international, open-access journal publishing top-quality, novel methods and technology development, as well as significant improvements to established techniques in basic, translational, and clinical cell and gene therapy.

19 August 2022 in Transplant Immunology
Verified
Journal Article
Closed access
ESE.X. Shao
E.X. Shao
BBBrigid Betz-Stablein
Brigid Betz-Stablein
LML. Marquat
L. Marquat
SCS. Campbell
S. Campbell
NINicole Isbel
Nicole Isbel
EPE.I. Plasmeijer
E.I. Plasmeijer

14 July 2012 in Transplant International
Verified
Journal Article
Open access
PDF file
Wai LimWai Lim
Wai Lim
PCPhilip Clayton
Philip Clayton
GWGermaine Wong
Germaine Wong
GDGursharan Dogra
Gursharan Dogra
CBCharley A. Budgeon
Charley A. Budgeon
SMStephen P. McDonald
Stephen P. McDonald
The association between pretransplant dialysis modality and transplant outcomes remains inconsistent. The aim of this study is to address the association between alteration in dialysis modality and post-transplant outcomes. Using Australia and New Zealand Dialysis and Transplant Registry, primary live- and deceased-donor renal transplant recipients (RTR) between 1997 and 2009 were examined. Pre-emptive and multiple-organ transplants were excluded. The association between initial and pretransplant dialysis modality and transplant outcomes were examined. Of the 6701 RTR, 18.6% were initiated-maintained on peritoneal dialysis pretransplant (PD-PD), 9.2% were initiated on PD, but maintained on haemodialysis (HD) pretransplant (PD-HD), 63.3% were HD-HD and 8.9% were HD-PD. PD-HD [odds ratio(OR)1.44, 95% CI 1.21,1.72] and HD-HD (OR1.25, 95% CI 1.12,1.41) were associated with a significantly greater risk of slow graft function compared with the overall mean of the groups, whereas a change in initial dialysis modality from HD to pretransplant PD was associated with higher risk of overall graft failure [hazard ratio(HR)1.19, 95% CI 1.04,1.36) and recipient death (HR1.34, 95% CI 1.13,1.59). Our registry analysis suggest that dialysis modality pretransplant may affect transplant outcomes and future studies evaluating patient selection, choice of modality and/or potential interventions in the pre and post-transplant period may have a beneficial effect on post-transplant outcomes.

1 December 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
MSMathias Seviiri
Mathias Seviiri
MLMatthew H. Law
Matthew H. Law
JOJue Sheng Ong
Jue Sheng Ong
PGPuya Gharahkhani
Puya Gharahkhani
DNDale Nyholt
Dale Nyholt
Stuart MacGregorStuart MacGregor
Stuart MacGregor
Solid organ transplant recipients (SOTRs) have elevated risks for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), especially in high UVR environments. We assessed whether polygenic risk scores can improve the prediction of BCC and SCC risks and multiplicity over and above the traditional risk factors in SOTRs in a high UV setting. We built polygenic risk scores for BCC (n = 594,881) and SCC (n = 581,431) using UK Biobank and 23andMe datasets, validated them in the Australian QSkin Sun and Health Study cohort (n > 6,300), and applied them in SOTRs in the skin tumor in allograft recipients cohort from Queensland, Australia, a high UV environment. About half of the SOTRs with a high genetic risk developed BCC (absolute risk = 45.45%, 95% confidence interval = 33.14-58.19%) and SCC (absolute risk = 44.12%, 95% confidence interval = 32.08-56.68%). For both cancers, SOTRs in the top quintile were at >3-fold increased risk relative to those in the bottom quintile. The respective polygenic risk scores improved risk predictions by 2% for BCC (area under the curve = 0.77 vs. 0.75, P = 0.0691) and SCC (area under the curve = 0.84 vs. 0.82, P = 0.0260), over and above the established risk factors, and 19.03% (for BCC) and 18.10% (for SCC) of the SOTRs were reclassified in a high/medium/low risk scenario. The polygenic risk scores also added predictive accuracy for tumor multiplicity (BCC R2 = 0.21 vs. 0.19, P = 3.2 × 10-3; SCC R2 = 0.30 vs. 0.27, P = 4.6 × 10-4).